ClinicalTrials.gg
RecruitingNCT04692818Updated Jun 1, 2026

3D Ultrasound Breast Imaging

An interventional study of GE Logiq E10 clinical ultrasound scanner and Verasonics research scanner in Breast Tumor, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Nov 2021; still recruiting 5 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
125
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 160 studies in Breast Neoplasms by Mayo Clinic — 30 open to participants now, 41 under way, 1 of them phase 3. Breast Neoplasms · Mayo Clinic.

Planned enrollment
18th of 97
125 · median 48
Started
2021
with 7 others
No phase
43 of 160
9 open now
Primary completion
2026-12
later than 3 of 40 live
Registered
105th of 160
by date

Among the 160 studies in Breast Neoplasms by Mayo Clinic, this one is the 18th largest by planned enrollment of the 97 interventional ones that give a count, is one of 8 that started in 2021, is one of 43 with no phase, reaches primary completion later than 3 of the 40 other live ones, and was the 105th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

30 of the 160 studies in Breast Neoplasms by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

25 more — sign in →

By country, each count listing its studies:

All 30 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 160 studies in Breast Neoplasms by Mayo Clinic, or all of them as a file.
02

Study summary

The purpose of this research is to study the efficacy of a new ultrasound imaging method for diagnosis of breast mass.

03

Conditions studied

  • Breast Tumor

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult women ≥ 18 years of age.
  • solid breast lesion and ultrasound guided (either as part of their clinical care or through participation in other IRB-approved studies)
  • lesion size of 3mm or larger

Exclusion criteria

Exclusion Criteria:

  • \< 18 years of age.
  • Lacking capacity to consent
  • Pregnant or lactating
  • Receiving cancer therapy such as chemotherapy or radiation therapy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
125 participants (estimated)

Study arms

  • Experimental
    Clinically indicated breast tumor biopsy

    Subjects with breast lesion and are scheduled for clinically-indicated biopsy will have 3D Multimodal Ultrasound Imaging performed

    Diagnostic Test: GE Logiq E10 clinical ultrasound scanner · Diagnostic Test: Verasonics research scanner

Interventions

  • Diagnostic testGE Logiq E10 clinical ultrasound scanner

    2D B-mode, Doppler, and shear wave elastography images of the lesion

  • Diagnostic testVerasonics research scanner

    3D B-mode imaging, microvessel imaging, and shear wave elastography

06

What researchers measure

Primary outcomes

  1. BI-RADS Score

    BI-RADS scores will be obtained using 2D B-mode ultrasound images from the GE Logiq E10 clinical scanner, and using 3D B-mode images from the Verasonics scanner. A 7-point BI-RADS scale will be used, with a score of 1, 2, or 3 considered negative and 4a, 4b, 4c, and 5 considered positive.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2021 (actual). Primary completion is estimated for Dec 2026, 61 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 61 months is above that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2020
First posted
Jan 5, 2021
StartActual
Nov 10, 2021
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04692818
Lead sponsor
Mayo Clinic
Collaborators
United States Department of Defense
Responsible party
Sponsor
First posted
Jan 5, 2021
Start date
Nov 10, 2021
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jun 1, 2026

Study contacts

Bobbie Ott
Contact
Ott.Bobbie@mayo.edu
507-293-0922
Shigao Chen, PhD
principal investigator · Mayo Clinic
Christine Lee, MD, PhD
principal investigator · Mayo Clinic in Rochester

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion